| Title |
A phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps
|
|---|---|
| Published in |
International Forum of Allergy & Rhinology, January 2018
|
| DOI | 10.1002/alr.22084 |
| Pubmed ID | |
| Authors |
Robert C. Kern, J. Pablo Stolovitzky, Stacey L. Silvers, Ameet Singh, Jivianne T. Lee, David M. Yen, Alfred M.C. Iloreta, Francis P.J. Langford, Boris Karanfilov, Keith E. Matheny, James W. Stambaugh, Anna K. Gawlicka, for the RESOLVE II study investigators |
| Abstract |
Topical intranasal corticosteroid sprays (INCSs) are standard treatment for nasal polyps (NPs), but their efficacy is reduced by poor patient compliance and impaired access of drug to the sinus mucosa. A corticosteroid-eluting sinus implant was designed to address these limitations in patients with recurrent polyposis after sinus surgery by delivering 1350 μg of mometasone furoate (MF) directly to the ethmoid sinus mucosa over approximately 90 days. A randomized, sham-controlled, double-blind trial was undertaken in 300 adults with refractory chronic rhinosinusitis with NPs (CRSwNP), who were candidates for repeat surgery. Eligible patients were randomized (2:1) and underwent in-office bilateral placement of 2 implants or a sham procedure. All patients used the MF INCS 200 μg once daily. Co-primary efficacy endpoints were the change from baseline in nasal obstruction/congestion score and bilateral polyp grade, as determined by an independent panel based on centralized, blinded videoendoscopy review. Patients treated with implants experienced significant reductions in both nasal obstruction/congestion score (p = 0.0074) and bilateral polyp grade (p = 0.0073) compared to controls. At day 90, implants were also associated with significant reductions in 4 of 5 prespecified secondary endpoints compared to control: proportion of patients still indicated for repeat sinus surgery (p = 0.0004), percent ethmoid sinus obstruction (p = 0.0007), nasal obstruction/congestion (p = 0.0248), and decreased sense of smell (p = 0.0470), but not facial pain/pressure (p = 0.9130). One patient experienced an implant-related serious adverse event (epistaxis). Significant improvements over a range of subjective and objective endpoints, including a reduction in the need for sinus surgery by 61%, suggest that MF sinus implants may play an important role in management of recurrent NP. |
X Demographics
The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 8 | 50% |
| Spain | 2 | 13% |
| Venezuela, Bolivarian Republic of | 2 | 13% |
| Côte d'Ivoire | 1 | 6% |
| Unknown | 3 | 19% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 11 | 69% |
| Practitioners (doctors, other healthcare professionals) | 4 | 25% |
| Scientists | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 107 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 107 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 9% |
| Student > Master | 10 | 9% |
| Student > Postgraduate | 8 | 7% |
| Other | 7 | 7% |
| Student > Ph. D. Student | 6 | 6% |
| Other | 21 | 20% |
| Unknown | 45 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 39 | 36% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Nursing and Health Professions | 4 | 4% |
| Business, Management and Accounting | 3 | 3% |
| Agricultural and Biological Sciences | 2 | 2% |
| Other | 8 | 7% |
| Unknown | 47 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 265. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 January 2022.
All research outputs
#129,301
of 24,477,448 outputs
Outputs from International Forum of Allergy & Rhinology
#8
of 1,818 outputs
Outputs of similar age
#3,191
of 450,597 outputs
Outputs of similar age from International Forum of Allergy & Rhinology
#1
of 54 outputs
Altmetric has tracked 24,477,448 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,818 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 450,597 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.